Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies
- سال انتشار: 1396
- محل انتشار: مجله بین المللی سیاست و مدیریت بهداشت، دوره: 6، شماره: 9
- کد COI اختصاصی: JR_HPM-6-9_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 204
نویسندگان
Department of Health Management, Evaluation and Policy, School of Public Health, University of Montreal, Montréal, QC, Canada
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Institute of Public Health Research of University of Montreal (IRSPUM), Montréal, QC, Canada
École Nationale d’administration publique (ENAP), Quebec City, QC, Canada
چکیده
Background New technologies constitute an important cost-driver in healthcare, but the dynamics that lead to their emergence remains poorly understood from a health policy standpoint. The goal of this paper is to clarify how entrepreneurs, investors, and regulatory agencies influence the value of emerging health technologies. Methods Our ۵-year qualitative research program examined the processes through which new health technologies were envisioned, financed, developed and commercialized by entrepreneurial clinical teams operating in Quebec’s (Canada) publicly funded healthcare system. Results Entrepreneurs have a direct influence over a new technology’s value proposition, but investors actively transform this value. Investors support a technology that can find a market, no matter its intrinsic value for clinical practice or healthcare systems. Regulatory agencies reinforce the “double” value of a new technology —as a health intervention and as an economic commodity— and provide economic worth to the venture that is bringing the technology to market. Conclusion Policy-oriented initiatives such as early health technology assessment (HTA) and coverage with evidence may provide technology developers with useful input regarding the decisions they make at an early stage. But to foster technologies that bring more value to healthcare systems, policy-makers must actively support the consideration of health policy issues in innovation policy.کلیدواژه ها
Innovation Policy, Health Policy, Health Technology Development (HTA), Technology-Based Ventures, Early HTAاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.